News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bio-Rad Laboratories, Inc. (BIO) and Lamprogen Partner to Commercialize Fluorescent Particles Used for Research



12/21/2012 8:00:40 AM

HERCULES, CA--(Marketwire - December 20, 2012) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced that they have entered into an agreement with Lamprogen, Inc. Under the terms of the agreement, Lamprogen grants Bio-Rad exclusive rights to commercialize a class of bright, stable, and non-toxic fluorescent particles for use in a broad array of assays and research applications including flow cytometry. Bio-Rad expects commercialization of the particles in 2013. As part of the agreement, Bio-Rad will also have access to future technologies developed by Lamprogen.

"Combining Lamprogen's unique fluorescent particles with antibodies or other biomolecules will enable our customers to create single and multiplex assays with greater detection capabilities," said Brad Crutchfield, Bio-Rad EVP and President, Life Science Group.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, please visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.


Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia
Corporate Communications
510-724-7000
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES